Research Experience

S.NoPhase of StudyIndication / CompoundSponsor# of Patients/SitesStatus
1PK Pilot Study
Hepatitis/Peg Interferon
UK based Multinational CompanyNational Pharma company
06/1
Completed (data used for the development of larger PK study)
2PK Study
Hepatitis/Peg Interferon
National Pharma company
16/1Completed (Poster presentation at EASL)
3PK Study
Diabetes/ Long acting Insulins
National Pharma company
14/1
Study Completed
4Phase II
Infectious diseases
Multinational Pharma Company
180/5
Study Completed
5Phase II
Vaccine
Multinational Pharma Company
170/1
Enrolment completed 03 months before plan. Study completed
6Phase II
Hemophilia (refractory patients)
Multinational Pharma company
05/1Enrolment planned to start in Q1 2014
7Phase III
Medical device (Cardiology)
Multinational Pharma Company
50/1
50% enrolment completed , Study On hold by sponsor
8Phase IV
Chronic Hepatitis C Infection
National Pharma Company
75/7
100% enrolment completed; Study planned to close in Q2 2013
9Phase IV
/Post Marketing Surveillance Study
Antibiotic
Multinational Pharma Company
230/43
Enrolment completed in 8 months , Study data locked , Paper writing in Progress
10Phase IV
/Post Marketing Surveillance Study
GynecologyMultinational Pharma Company
210/3088% enrolment completed
11Phase IV
/Post Marketing Surveillance Study
Migraine
Multinational Pharma Company
500 Total
100 for Pakistan
Planned to start in Q2 2013
12Observational Study
Chronic Hep C Infection
National Pharma Company
1050/60
20% enrolment completed in 2 months.
13Epidemiological Survey
ILD
Investigator Initiated + Pakistan Chest Society
500/5Data collection completed; paper writing in progress

 

Representation in the Ministry of Health Pakistan:

  • Member Experts Committee Pakistan GCP Guidelines development
  • Member GCP Inspection System guidelines development Committee
  • Trainer of Clinical Trial/Research Approvals group MoH
Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin